Cataplexy: 'Tonic immobility' rather than 'REM-sleep atonia'?

Sleep Medicine

Volumn 3, Issue 6, 2002, Pages 471-477

  Overeem, Sebastiaan ^a   Lammers, Gert Jan ^a   van Dijk, J Gert ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atavism; Atonia; Cataplexy; Narcolepsy; Rapid eye movement sleep; Tonic immobility

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CARBACHOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; IMIPRAMINE; IPRONIAZID; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; OREXIN; PRAZOSIN; SULPIRIDE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CATAPLEXY; DOSE RESPONSE; EMOTION; HAZARD; HUMAN; HYPOTHALAMUS; HYPOTHESIS; MUSCLE ATONIA; NARCOLEPSY; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REM SLEEP; SYMPTOMATOLOGY; THEORY; TONIC IMMOBILITY;

EID: 0036865307     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1389-9457(02)00037-0     Document Type: Article

References (79)

1. Yoss RE, Daly DD. Criteria for the diagnosis of the narcoleptic syndrome. Proc Staff Meet Mayo Clin 1957;32:320-328.
2. Bassetti C, Aldrich MS. Narcolepsy. Neurol Clin 1996;14(3):545-571.
3. Overeem S, Mignot E, van Dijk JG, Lammers GJ. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 2001;18(2):78-105.
4. Browman CP, Gujavarty KS, Yolles SF, Mitler MM. Forty-eight-hour polysomnographic evaluation of narcolepsy. Sleep 1986;9(1 Pt 2):183-188.
5. Hishikawa Y, Kaneko Z. Electroencephalographic study on narcolepsy. Electroencephalogr clin Neurophysiol 1965;18:249-259.
6. Roth B, Bruhova S, Lehovsky M. REM sleep and NREM sleep in narcolepsy and hypersomnia. Electroencephalogr clin Neurophysiol 1969;26(2):176-182.
7. Broughton R, Valley V, Aguirre M, Roberts J, Suwalski W, Dunham W. Excessive daytime sleepiness and the pathophysiology of narcolepsy-cataplexy: a laboratory perspective. Sleep 1986;9(1 Pt 2):205-215.
8. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98(3):365-376.
9. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98(4):437-451.
10. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355(9197):39-40.
11. Nishino S, Ripley B, Overeem S, et al. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001;50(3):381-388.
12. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998;95(1):322-327.
13. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92(4):573-585.
14. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6(9):991-997.
15. Peyron C, Tighe DK, Den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998;18(23):9996-10015.
16. Klemm WR. Neurophysiologic studies of the immobility reflex ('animal hypnosis'). Neurosci Res (NY) 1971;4:165-212.
17. Gallup Jr GG. Animal hypnosis: factual status of a fictional concept. Psychol Bull 1974;81(11):836-853.
18. Anic-Labat S, Guilleminault C, Kraemer HC, Meehan J, Arrigoni J, mignot E. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep 1999;22(1):77-87.
19. Provine RR. Laughter: a scientific investigation. London: Faber and Faber, 2000.
20. Riehl J, Nishino S, Cederberg R, Dement WC, Mignot E. Development of cataplexy in genetically narcoleptic Dobermans. Exp Neurol 1998;152(2):292-302.
21. Willie JT, Chemelli RM, Xiong Y, Yanagisawa M. A behavioral paradigm that elicits narcoleptic attacks in orexin knockout mice [abstract]. Sleep 2000;23(Suppl 2):A91-A92.
22. Kushida CA, Baker TL, Dement WC. Electroencephalographic correlates of cataplectic attacks in narcoleptic canines. Electroencephalogr clin Neurophysiol 1985;61(1):61-70.
23. Guilleminault C, Wilson RA, Dement WC. A study on cataplexy. Arch Neurol 1974;31(4):255-261.
24. Rubboli G, d'Orsi G, Zaniboni A, et al. A video-polygraphic analysis of the cataplectic attack. Clin Neurophysiol 2000;111 (Suppl 2):S120-S128.
25. Guilleminault C, Gelb M. Clinical aspects and features of cataplexy. Adv Neurol 1995;67:65-77.
26. Siegel JM, Tomaszewski KS, Fahringer H, Cave G, Kilduff T, Dement WC. Heart rate and blood pressure changes during sleepwaking cycles and cataplexy in narcoleptic dogs. Am J Physiol 1989;256(1 Pt 2):H111-H119.
27. Guilleminault C, Heinzer R, Mignot E, Black J. Investigations into the neurologic basis of narcolepsy. Neurology 1998;50(2 Suppl 1):S8-S15.
28. Nishino S, Reid MS, Dement WC, Mignot E. Neuropharmacology and neurochemistry of canine narcolepsy. Sleep 1994;17(Suppl 8):S84-S92.
29. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997;52(1):27-78.
30. Hishikawa Y, Shimizu T. Physiology of REM sleep, cataplexy, and sleep paralysis. Adv Neurol 1995;67:245-271.
31. Thorpy M. Current concepts in the etiology, diagnosis and treatment of narcolepsy. Sleep Med 2001;2(1):5-17.
32. Guilleminault C, Mignot E, Aldrich M, Quera-Salva MA, Tiberge M, Partinen M. Prazosin contraindicated in patients with narcolepsy. Lancet 1988;2(8609):511.
33. Aldrich MS, Rogers AE. Exacerbation of human cataplexy by prazosin. Sleep 1989;12(3):254-256.
34. Nishino S, Tafti M, Reid MS, et al. Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsy. J Neurosci 1995;15(7 Pt 1):4806-4814.
35. Reid MS, Nishino S, Tafti M, Siegel JM, Dement WC, Mignot E. Neuropharmacological characterization of basal forebrain cholinergic stimulated cataplexy in narcoleptic canines. Exp Neurol 1998;151(1):89-104.
36. Mignot E. Pathophysiology of narcolepsy. In: Kryger MH, Roth T, Dement W, editors. Principles and practice of sleep medicine. Philadelphia, PA: Saunders, 2000. pp. 663-675.
37. Aserinsky E, Kleitman N. Regularly occurring periods of eye motility, and concomitant phenomena during sleep. Science 1953;118:273-274.
38. Siegel JM. Brainstem mechanisms generating REM sleep. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Philadelpia, PA: W.B. Saunders, 2000. pp. 112-133.
39. Dement WC, Kleitman N. Cyclic variations in EEG during sleep and their relation to eye movements, body motility, and dreaming. Electroencephalogr clin Neurophysiol 1957;9:673-690.
40. Vogel G. Studies in psychophysiology of dreams. III. The dream of narcolepsy. Arch Gen Psychiatry 1960;3:421-428.
41. Rechtschaffen A, Wolpert EA, Dement WC, Mitchell SA, Fischer C. Nocturnal sleep of narcoleptics. Electroencephalogr clin Neurophysiol 1963;15:599-609.
42. Siegel JM, Nienhuis R, Fahringer HM, et al. Neuronal activity in narcolepsy: identification of cataplexy-related cells in the medial medulla. Science 1991;252(5010):1315-1318.
43. Wu MF, Gulyani SA, Yau E, Mignot E, Phan B, Siegel JM. Locus coeruleus neurons: cessation of activity during cataplexy. Neuroscience 1999;91(4):1389-1399.
44. Nishino S, Okura M, Mignot E. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med Rev 2000;4(1):57-99.
45. Nishino S, Riehl J, Hong J, Kwan M, Reid MS, Mignot E. Is narcolepsy a REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans. Neurosci Res 2000;38:437-446.
46. Ohayon MM, Priest RG, Caulet M, Guilleminault C. Hypnagogic and hypnopompic hallucinations: pathological phenomena? Br J Psychiatry 1996;169(4):459-467.
47. Ohayon MM, Zulley J, Guilleminault C, Smirne S. Prevalence and pathologic associations of sleep paralysis in the general population. Neurology 1999;52(6):1194-1200.
48. Ohayon MM. Prevalence of hallucinations and their pathological associations in the general population. Psychiatry Res 2000;97(23):153-164.
49. Parkes JD. Sleep and its disorders. London: Saunders, 1985.
50. Guilleminault C. Cataplexy. In: Guilleminault C, Dement WC, Passouant P, editors. Narcolepsy. New York, NY: Spectrum, 1976. pp. 125-144.
51. Lammers GJ, Overeem S, Tijssen MA, van Dijk JG. Effects of startle and laughter in cataplectic subjects: a neurophysiological study between attacks. Clin Neurophysiol 2000;111(7):1276-1281.
52. Overeem S, Lammers GJ, van Dijk JG. Weak with laughter. Lancet 1999;354(9181):838.
53. Szymusiak R, Alam N, McGinty D. Discharge patterns of neurons in cholinergic regions of the basal forebrain during waking and sleep. Behav Brain Res 2000;115(2):171-182.
54. Vazquez J, Baghdoyan HA. Basal forebrain acetylcholine release during REM sleep is significantly greater than during waking. Am J Physiol Regul Integr Comp Physiol 2001;280(2):R598-R601.
55. Okura M, Riehl J, Mignot E, Nishino S. Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep incanine narcolepsy. Neuropsychopharmacology 2000;23(5):528-538.
56. Reid MS, Tafti M, Nishino S, Sampathkumaran R, Siegel JM, Mignot E. Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine. Brain Res 1996;733(1):83-100.
57. Honda K, Riehl J, Mignot E, Nishino S. Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep [corrected] [corrected and republished in NeuroReport, Nov 26;10(17):3717-24]. NeuroReport 1999;10(14):3111-3118.
58. Miller JD, Farber J, Gatz P, Roffwarg H, German DC. Activity of mesencephalic dopamine and non-dopamine neurons across stages of sleep and waking in the rat. Brain Res 1983;273:133-141.
59. Zepelin H. Mammalian sleep. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Philadelphia, PA: Saunders, 2000. pp. 82-92.
60. Erhard HW, Mendl M, Cloutier R, Christiansen SB. Individual differences in tonic immobility may reflect behavioural strategies. Appl Anim Behav Sci 1999;64:31-46.
61. Andersen IL, Boe KE, Foerevik G, Janczak AM, Bakken M. Behavioural evaluation of methods for assessing fear responses in weaned pigs. Appl Anim Behav Sci 2000;69(3):227-240.
62. Klemm WR. Use of the immobility reflex ('animal hypnosis') in neuropharmacological studies. Pharmacol Biochem Behav 1976;4(1):85-94.
63. Ginsburg HJ. Defensive distance and immobility in young precocial birds (Gallus gallus). Dev Psychobiol 1975;8(3):281-285.
64. Kimble DP. Didelphid behavior. Neurosci Behav Rev 1997;21(3):361-369.
65. Klemm WR. Drug effects on active immobility responses: what they tell us about neurotransmitter systems and motor functions. Prog Neurobiol 1989;32:403-422.
66. Carli G. Depression of somatic reflexes during rabbit hypnosis. Brain Res 1968;11:453-456.
67. Braun CM, Pivik RT. Effects of brainstem lesions on tonic immobility in the rabbit (Oryctolagus cuniculus). Brain Res Bull 1983;10(1):127-135.
68. Klemm WR. Identity of sensory and motor systems that are critical to the immobility reflex ('animal hypnosis'). J Neurosci Res 1976;2(1):57-69.
69. Woodruff ML, Lippincott WI. Hyperemotionality and enhanced tonic immobility after septal lesions in the rabbit. Brain Behav Evol 1976;13(1):22-33.
70. Hennig CW, McIntyre JF, Moriarty Jr DD, Picerno JM, Allen JL. Differential cholinergic influences on the immobility response in various strains of domestic fowl. Pharmacol Biochem Behav 1988;30(3):625-634.
71. Franchi CR, Hoffmann V, Hoffmann A. Involvement of the cholinergic system and the basal midbrain in the organization of tonic immobility in the toad Bufo paracnemis. Physiol Behav 1994;55(5):831-837.
72. de Oliveira L, Hoffmann A, Menescal-de-Oliveira L. Participation of the medial and anterior hypothalamus in the modulation of tonic immobility in guinea pigs. Physiol Behav 1997;62(5):1171-1178.
73. de Oliveira L, Hoffmann A, Menescal-de-Oliveira L. The lateral hypothalamus in the modulation of tonic immobility in guinea pigs. NeuroReport 1997;8(16):3489-3493.
74. Hall BK. Atavisms and atavistic mutations. Nat Gen 1995;10:126-127.
75. Reese WG, Newton JE, Angel C. Induced immobility in nervous and normal Pointer dogs. J Nerv Ment Dis 1982;170(10):605-613.
76. Willie JT, Chemelli RM, Sinton CM, Yanagisawa M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci 2001;24:429-458.
77. Liberson WT, Ellen P, Schwartz E, Wilson A, Gagnon VP. Further studies of the effects of psychotropic drugs on the behavior of guinea pigs and rats. J Neuropsychiatry 1962;3:298-303.
78. Maser JD, Gallup Jr GG. Tonic immobility in the chicken: catalepsy potentiation by uncontrollable shock and alleviation by imipramine. Psychosom Med 1974;36(3):199-205.
79. Bassetti CL, Gugger M, Mathis J, Sturznegger C, Radanov B, Ripley B, Nishino S, Mignot E. Cerebrospinal fluid levels of hypocretin (orexin) in hypersomnolent patients without cataplexy. Actas Fisiologia 2001;7:205.